$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > PARP抑制剂

卵巢癌|卵巢癌治疗

超七成患者确诊已是晚期!打破卵巢癌反复复发的死循环,是目前治疗方
中晚期卵巢癌靶向药治疗全解:一线维持治疗具体怎么做?

胰腺癌|胰腺癌特药

奥拉帕利(olaparib,商品名Lynparza)获欧盟批准一线维持治疗BRCA

奥拉帕利|上市信息

奥拉帕利(olaparib,商品名Lynparza)获欧盟批准一线维持治疗BRCA